Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease
Biopharmacology, Eisai Limited, European Knowledge Centre, Mosquito Way, Hartfield, Hertfordshire, AL10 9SN, UK
Alzheimer's Research & Therapy 2012, 4:32 doi:10.1186/alzrt135Published: 27 August 2012
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterised by extracellular amyloid-ß (Aß) and intraneuronal tau protein brain pathologies. The most significant risk factor for non-familial AD is the presence of the E4 isoform of the cholesterol transporter apolipoprotein E (apoE). Despite extensive basic research, the exact role of apoE in disease aetiology remains unclear. Correspondingly, therapeutic targeting of apoE in AD is at an early preclinical stage. In this review, I discuss the key interactions of apoE and Aß pathology, the current progress of preclinical animal models and the caveats of existing therapeutic approaches targeting apoE. Finally, novel Alzheimer's genetics and Aß-independent disease mechanisms are highlighted.